Table 1.
Clinical and pathologic features by racial/age group
| Young Black | Young White | Older Black | Older White | p-value† | |
|---|---|---|---|---|---|
| N = 151 | N = 235 | N = 828 | N = 982 | ||
| Age at diagnosis (years) | 34.5 (4.8) | 35.3 (4.0) | 68.8 (8.8) | 65.9 (8.1) | NR |
| Tumor size (mm) | 36.3 (26.7) | 30.4 (24.4) | 23.3 (21.2) | 21.8 (19.8) | < 0.001* |
| Lymph node status | < 0.001 | ||||
| 0 | 56 (45.5%) | 123 (59.4%) | 482 (69.1%) | 599 (69.7%) | |
| 1–3 | 50 (40.7%) | 53 (25.6%) | 153 (21.9%) | 186 (21.7%) | |
| 4–9 | 9 (7.3%) | 24 (11.6%) | 43 (6.2%) | 51 (5.9%) | |
| 10 + | 8 (6.5%) | 7 (3.4%) | 20 (2.9%) | 23 (2.7%) | |
| Receptor status | < 0.001 | ||||
| HR + /HER2− | 48 (39.7%) | 108 (52.2%) | 471 (64.0%) | 675 (76.3%) | |
| HR + /HER2 + | 16 (13.2%) | 38 (18.4%) | 56 (7.6%) | 72 (8.1%) | |
| HR−/HER2 + | 11 (9.1%) | 13 (6.3%) | 40 (5.4%) | 47 (5.3%) | |
| TNBC | 46 (38.0%) | 48 (23.2%) | 169 (23.0%) | 91 (10.3%) | |
| Stage | < 0.001 | ||||
| 1 | 31 (20.5%) | 84 (35.7%) | 412 (49.8%) | 548 (55.8%) | |
| 2 | 75 (49.7%) | 112 (47.7%) | 315 (38.0%) | 335 (34.1%) | |
| 3 | 45 (29.8%) | 39 (16.6%) | 101 (12.2%) | 99 (10.1%) | |
| Tumor grade | < 0.001 | ||||
| 1 | 7 (5%) | 17 (8%) | 115 (15%) | 173 (19%) | |
| 2 | 42 (31%) | 80 (36%) | 338 (44%) | 509 (55%) | |
| 3 | 88 (64%) | 128 (57%) | 323 (42%) | 242 (26%) |
Data are presented as mean (SD) for continuous measures, and n(%) for categorical measures
HR hormone receptor, HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer, NR not relevant
†Chi-squared test, except *ANOVA